TGF-β Signaling and Resistance to Cancer Therapy

Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance

(2021) Mohammad Jalalirad et al.   ONCOGENE

Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer

(2021) Baotong Zhang et al.   Nature Communications

A tumor-specific mechanism of Treg enrichment mediated by the integrin αvβ8

(2021) Robert I. Seed et al.   Science Immunology

TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model

(2021) Nourridine Siewe et al.   PLoS One

Combined Blockade of GARP:TGF-β1 and PD-1 Increases Infiltration of T Cells and Density of Pericyte-Covered GARP+ Blood Vessels in Mouse MC38 Tumors

(2021) Charlotte Bertrand et al.   Frontiers in Immunology

GARP: A Key Target to Evaluate Tumor Immunosuppressive Microenvironment

(2021) Alexanne Bouchard et al.   Biology-Basel

A review of cancer immunotherapy toxicity

(2020) Lucy Boyce Kennedy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity

(2020) Shannon Lee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1

(2020) Liqiang Chen et al.   Bioengineered

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

(2020) Hanne Lind et al.   Journal for ImmunoTherapy of Cancer

Leptin acts on mesenchymal stem cells to promote chemoresistance in osteosarcoma cells

(2020) Helin Feng et al.   Aging-US

TGF-beta: a master immune regulator

(2020) Christopher Larson et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer

(2020) Wenwen Du et al.   ONCOLOGY REPORTS

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape

(2020) Constance J. Martin et al.   Science Translational Medicine

Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

(2020) Suresh Bugide et al.   Oncogenesis

Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.

(2020) D. Ciardiello et al.   ANNALS OF ONCOLOGY

Fucoidan increased the sensitivity to gefitinib in lung cancer cells correlates with reduction of TGFβ-mediated Slug expression

(2020) Wei-Lun Qiu et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

MiR-216b/Smad3/BCL-2 Axis Is Involved in Smoking-Mediated Drug Resistance in Non-Small Cell Lung Cancer

(2020) Trung Vu et al.   Cancers

Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR–TKI Tolerance and Lung Cancer Dissemination

(2020) Ming-Han Kuo et al.   CANCER RESEARCH

TGF-β suppresses type 2 immunity to cancer

(2020) Ming Liu et al.   NATURE

Cancer immunotherapy via targeted TGF-β signalling blockade in TH cells

(2020) Shun Li et al.   NATURE

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer

(2020) Grégoire de Streel et al.   Nature Communications

ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions

(2019) Qianting Zhang et al.   NATURE CELL BIOLOGY

TGF-β-induced alternative splicing of TAK1 promotes EMT and drug resistance

(2019) Veenu Tripathi et al.   ONCOGENE

α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

(2019) E. Dodagatta-Marri et al.   Journal for ImmunoTherapy of Cancer

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

(2019) Liam Cornell et al.   Cell Reports

From poor prognosis to promising treatment

(2019) Daniele V. F. Tauriello   SCIENCE

The relationship between autophagy and the immune system and its applications for tumor immunotherapy

(2019) Guan-Min Jiang et al.   Molecular Cancer

HERC3-mediated SMAD7 ubiquitination degradation promotes autophagy-induced EMT and chemoresistance in glioblastoma

(2019) Hong Li et al.   CLINICAL CANCER RESEARCH

Dual role of TGF-B in early pregnancy: Clues from tumor progression

(2019) Zeinab Latifi et al.   BIOLOGY OF REPRODUCTION

MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer

(2019) Ping Zhao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Transforming Growth Factor-β Signaling in Immunity and Cancer

(2019) Eduard Batlle et al.   IMMUNITY

The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells

(2019) Tian Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models

(2019) Heng Sheng Sow et al.   Cells

ERK regulates HIF-1α-mediated platinum resistance by directly targeting PHD2 in ovarian cancer

(2019) Zhuqing Li et al.   CLINICAL CANCER RESEARCH

Blockade of TGF-β signaling: a potential target for cancer immunotherapy?

(2019) Hendrik Ungefroren   EXPERT OPINION ON THERAPEUTIC TARGETS

PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling

(2019) Qiuying Quan et al.   ONCOLOGY RESEARCH

Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance

(2019) Shun Li et al.   Nature Communications

Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages

(2019) Hao-Yu Chuang et al.   Journal of Clinical Medicine

TFEB-driven autophagy potentiates TGF-β induced migration in pancreatic cancer cells

(2019) Ruizhi He et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR

(2019) Ella Bhagyaraj et al.   CELL CYCLE

Circular RNA cESRP1 sensitises small cell lung cancer cells to chemotherapy by sponging miR-93-5p to inhibit TGF-β signalling

(2019) Weimei Huang et al.   CELL DEATH AND DIFFERENTIATION

Micropeptide CIP 2A‐ BP encoded by LINC 00665 inhibits triple‐negative breast cancer progression

(2019) Binbin Guo et al.   EMBO JOURNAL

Impairment of NKG2D-Mediated Tumor Immunity by TGF-β

(2019) Mariya Lazarova et al.   Frontiers in Immunology

TGFβ induces stemness through non-canonical AKT-FOXO3a axis in oral squamous cell carcinoma

(2019) Kan Li et al.   EBioMedicine

TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis

(2018) Xiaodan Xu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer

(2018) Xinliang Zhou et al.   CANCER GENE THERAPY

TGF-β Inhibition and Immunotherapy: Checkmate

(2018) Karuna Ganesh et al.   IMMUNITY

miR-190 suppresses breast cancer metastasis by regulation of TGF-β-induced epithelial–mesenchymal transition

(2018) Yue Yu et al.   Molecular Cancer

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

(2018) Christopher C. Kloss et al.   MOLECULAR THERAPY

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer

(2018) Yen-An Tang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

(2018) Yan Lan et al.   Science Translational Medicine

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

(2018) Scott J. Rodig et al.   Science Translational Medicine

Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy

(2018) Rajani Ravi et al.   Nature Communications

Cancer immunotherapy: broadening the scope of targetable tumours

(2018) Jitske van den Bulk et al.   Open Biology

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

TGF-β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer

(2018) Channing Paller et al.   PROSTATE

TGFβ-Activated USP27X Deubiquitinase Regulates Cell Migration and Chemoresistance via Stabilization of Snail1

(2018) Guillem Lambies et al.   CANCER RESEARCH

Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression

(2018) Bing Song et al.   JOURNAL OF CLINICAL INVESTIGATION

TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer

(2018) Daniel R Principe et al.   MOLECULAR CANCER THERAPEUTICS

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

(2018) Razvan Cristescu et al.   SCIENCE

Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer

(2018) Xin Wu et al.   Cell Death & Disease

Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium

(2018) Luca Falzone et al.   Frontiers in Pharmacology

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)

(2017) Jia Zhong et al.   Journal of Thoracic Oncology

Breast cancer

(2017) Nadia Harbeck et al.   LANCET

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

(2017) Hezhe Lu et al.   NATURE

TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function

(2017) D R Principe et al.   ONCOGENE

MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway

(2017) Lisa Koetz-Ploch et al.   Pigment Cell & Melanoma Research

A New View of Pathway-Driven Drug Resistance in Tumor Proliferation

(2017) Ruth Nussinov et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-β/Smad4 pathway

(2017) Chen Sun et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT

(2017) Qiuli Liu et al.   Cell Death & Disease

Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC

(2017) Junchao Cai et al.   Nature Communications

TGFβ1 Promotes Gemcitabine Resistance through Regulating the LncRNA-LET/NF90/miR-145 Signaling Axis in Bladder Cancer

(2017) Junlong Zhuang et al.   Theranostics

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

(2017) Justin M. David et al.   OncoImmunology

High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells

(2016) Sina Oppermann et al.   BLOOD

TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3

(2016) Rachel A. Hesler et al.   CARCINOGENESIS

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer

(2016) D. Kazandjian et al.   CLINICAL CANCER RESEARCH

Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation

(2016) RYOTA KURIMOTO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Cathepsin-B-mediated cleavage of Disabled-2 regulates TGF-β-induced autophagy

(2016) Yong Jiang et al.   NATURE CELL BIOLOGY

Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells

(2016) F Faião-Flores et al.   ONCOGENE

Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β–dependent mechanisms

(2016) Xiarong Shi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Signaling Receptors for TGF-β Family Members

(2016) Carl-Henrik Heldin et al.   Cold Spring Harbor Perspectives in Biology

The Discovery and Early Days of TGF-β: A Historical Perspective

(2016) Harold L. Moses et al.   Cold Spring Harbor Perspectives in Biology

TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology

(2016) Masato Morikawa et al.   Cold Spring Harbor Perspectives in Biology

ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma

(2016) Jun Li et al.   Cell Death & Disease

TGF 1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer

(2016) B. V. Park et al.   Cancer Discovery

TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype

(2016) Fan Zhang et al.   Oncotarget

Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition

(2015) M. Soucheray et al.   CANCER RESEARCH

TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma

(2015) Naoki Oshimori et al.   CELL

The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells

(2015) Michele Cioffi et al.   GUT

BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic Escape

(2015) Inna V. Fedorenko et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells

(2015) Molly H. Jenkins et al.   MATRIX BIOLOGY

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

(2015) Xiaofeng Zheng et al.   NATURE

Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance

(2015) Kari R. Fischer et al.   NATURE

Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

(2015) Alexandre Calon et al.   NATURE GENETICS

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients

(2015) Maria Serova et al.   Oncotarget

Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy

(2015) Oana Draghiciu et al.   OncoImmunology

Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway

(2014) B Zhang et al.   BRITISH JOURNAL OF CANCER

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer

(2014) Wen-Dong Bai et al.   INTERNATIONAL JOURNAL OF CANCER

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

miRNA 17 Family Regulates Cisplatin-Resistant and Metastasis by Targeting TGFbetaR2 in NSCLC

(2014) Zeyong Jiang et al.   PLoS One

TGF-β: An emerging player in drug resistance

(2013) Diede Brunen et al.   CELL CYCLE

HER2-positive gastric cancer

(2013) Narikazu Boku   Gastric Cancer

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

(2013) Alberto Antonicelli et al.   International Journal of Medical Sciences

Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/EnzalutamideversusAnti-androgen Receptor ASC-J9® Lead to PromotionversusSuppression of Prostate Cancer Metastasis

(2013) Tzu-Hua Lin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer

(2013) Neil E. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells

(2013) Masakuni Serizawa et al.   Journal of Thoracic Oncology

Differential regulation of the REGγ–proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells

(2013) Amjad Ali et al.   Nature Communications

Dynamics and feedback loops in the transforming growth factor β signaling pathway

(2012) Katja Wegner et al.   BIOPHYSICAL CHEMISTRY

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

(2012) Sidong Huang et al.   CELL

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

(2012) Libero Santarpia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma

(2012) Michael P. Smith et al.   JNCI-Journal of the National Cancer Institute

Cdk4/6 Inhibition Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells

(2012) F. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of TGF-  Enhances the In Vivo Antitumor Efficacy of EGF Receptor-Targeted Therapy

(2012) A. Bedi et al.   MOLECULAR CANCER THERAPEUTICS

Dynamics of TGF-  signaling reveal adaptive and pulsatile behaviors reflected in the nuclear localization of transcription factor Smad4

(2012) A. Warmflash et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells

(2011) Jayashree P. Joshi et al.   BIOCHEMICAL PHARMACOLOGY

Quantitative analysis of transient and sustained transforming growth factor-  signaling dynamics

(2011) Z. Zi et al.   Molecular Systems Biology

PKCα-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-β1

(2010) Ying Chen et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

TGF-  IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

(2010) Z. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression

(2010) Li Yang et al.   TRENDS IN IMMUNOLOGY

Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN

(2009) Zvi G. Fridlender et al.   CANCER CELL

Transforming Growth Factor   Induces Clustering of HER2 and Integrins by Activating Src-Focal Adhesion Kinase and Receptor Association to the Cytoskeleton

(2009) S. E. Wang et al.   CANCER RESEARCH

Localized and reversible TGFβ signalling switches breast cancer cells from cohesive to single cell motility

(2009) Silvia Giampieri et al.   NATURE CELL BIOLOGY

TGFβ in Cancer

(2008) Joan Massagué   CELL

The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner

(2008) Alessandro Sorrentino et al.   NATURE CELL BIOLOGY